LY 233053 

LY 233053 is a potent and competitive NMDA-receptor antagonist with anticonvulsant and antiepileptic efficacy^[1][2].

LY 233053 (0.5 and 5 mg/kg) has no effects on the electroconvulsive threshold but potentiated the anticonvulsant action of all antiepileptics studied^[1].
LY 233053 (5 mg/kg) with carbamazepine, diphenylhydantoin, or phenobarbital provides a 50% protection against maximal electroshock, and results in the impairment of long-term memory^[1].
LY233053 (intravenous bolus injection;100 mg/kg; administered 5, 30, or 60 minutes after reversible spinal cord ischemia) is effective in limiting ischemic damage, but protection is lost if therapy is not initiated within 60 minutes of injury in New zealand White rabbits^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

211.22

C₈H₁₃N₅O₂

125546-04-5

OC([C@@H](NCC1)C[C@@H]1CC2=NN=NN2)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. 1.K K Borowicz, et al. Competitive NMDA-receptor antagonists, LY 235959 and LY 233053, enhance the protective efficacy of various antiepileptic drugs against maximal electroshock-induced seizures in mice. Epilepsia. 1996 Jul;37(7):618-24.  [Content Brief]

  [2]. K P Madden, et al. Efficacy of LY233053, a competitive glutamate antagonist, in experimental central nervous system ischemia. J Neurosurg. 1992 Jan;76(1):106-10.  [Content Brief]